Skip to content

News & updates

Media Coverage

MiRXES ranked top 200 in FT/Nikkei Asia-Pacific High-Growth Companies 2021
Success Stories: MiRXES Japan
MiRXES test kit that can detect COVID-19 and seasonal flu gets HSA’s approval
COVID-19 and the coming of age of Singapore science
MiRXES Chief Scientific Advisor in SWITCH 2020 Video: 25 People, One Story (Video)
MiRXES CEO on SWITCH 2020 panel: Internationalisation of deep tech (Video)
MiRXES sets out to sell gastric cancer test across Asia
Channel News Asia report on GASTROClear (Video)
GASTROClear being evaluated for use in primary healthcare
IPOS Innovation for Humanity Award for MiRXES (Video)
Singapore ramps up test kit production to meet local and global demand
MiRXES and other homegrown firms in virus fight
MiRXES leading the way in microRNA technology
Home-grown firms linked to pandemic work will continue to attract demand, investments
MiRXES is 102nd on Financial Times ranking of Asia-Pacific High Growth Companies
COVID-19 putting MiRXES and Singapore on global deeptech radar
MiRXES heeding the call for COVID-19 testing
MiRXES — A game changer in microRNA applications
Singapore clears Fortitude Kit SARS-CoV-2 test for clinical use
MiRXES to mass-produce Singapore-developed Fortitude Kit SARS-CoV-2 test kits
MiRXES named Singapore’s fastest growing company in the health sector from 2015-2018
Timely guidance for MiRXES from Pro-Enterprise Panel
GASTROClear blood test for stomach cancer first step to ending all cancer deaths
MiRXES has a real shot at stamping out cancer deaths
Seniors tested for stomach cancer with GASTROClear at free screening in Teck Ghee
MiRXES co-founder Zhou Lihan’s entrepreneurial journey
MiRXES collaborates with Johnson & Johnson to develop miRNA test for lung cancer
MiRXES aims to make cancer tests more accessible
Venturecraft invests in MiRXES